Stock listing

Frankfurt:1RT Nuformix PLC Aktie

German listing (Frankfurt) of Nuformix PLC · home listing LSE:NFX

Follow Nuformix PLC into a list and get an email when it puts out news.

Share price · FWB:1RT

€0.0010 EUR 0.0000 (0.0%)

Close on Nov 20, 2026

Past year -50.0% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits
Day range
€0.0010 – €0.0010 EURNov 20, 2026
Market cap
€2.61M EURAt the close on Nov 20, 2026 · price × 2.61B shares outstanding
52-week range
€0.0010 – €0.0020 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€9 EURMedian day 0 shares · 56 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
Nuformix PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:NFX · Home0.065p GBX (pence)0.000 (0.0%)49,893,9920.065p0.067p0.053p0.065pClose on Nov 20, 2026
Frankfurt:1RT€0.0010 EUR0.0000 (0.0%)—€0.0010€0.0010€0.0010€0.0010Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:1RT · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.0010500,000
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.0010-0.0010-50.0%€0.0010€0.0010€0.00100
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
€0.00200.00000.0%€0.0020€0.0020€0.00200
Ticker
Frankfurt:1RT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

NXP002 Development Update

Oct 19, 2026

Closed €0.0010 (0.0%) on Oct 19, 2026

Appointment of Chairman

Aug 25, 2026

Closed €0.0020 (0.0%) on Aug 25, 2026

Half Year Report

May 28, 2026

Closed €0.0010 (0.0%) on May 28, 2026

Total Voting Rights

Mar 31, 2026

Closed €0.0010 (0.0%) on Apr 1, 2026

£1.0 million Placing

Mar 11, 2026

Closed €0.0010 (0.0%) on Mar 11, 2026

Confirmation of US ODD for NXP002 in IPF

Mar 10, 2026

Closed €0.0010 (0.0%) on Mar 10, 2026

Result of AGM

Mar 3, 2026

Closed €0.0010 (0.0%) on Mar 3, 2026

Posting of Annual Report and Notice of AGM

Feb 5, 2026

Closed €0.0010 (0.0%) on Feb 5, 2026

All Nuformix PLC news

Nuformix PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
11 in the last 12 months · 138 in all · newest Nov 11, 2026 · oldest 2015
Decks
3 decks · latest Nov 9, 2022

Where Nuformix PLC is listed

ListingExchangeCountryCurrency
LSE:NFX · Home listingLSEUnited KingdomGBX
Lang & Schwarz:A141LGLang & SchwarzGermanyEUR
LS Exchange:A141LGLS ExchangeGermanyEUR
Frankfurt:1RT · This pageFrankfurtGermanyEUR
Stuttgart:1RTStuttgartGermanyEUR

Valuation

Price/book 1.0× against a median of 0.3×: 7th lowest of 8 Biotechnology companies shown. Statements: Year to Sep 30, 2025 · balance Mar 31, 2026 · price Nov 20, 2026

Enterprise value
£766,054 GBP
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Nuformix PLC · LSE:NFXUS$2.22MUS$1.00Mn/an/an/a1.0×n/a0.0×n/a
Revelation Biosciences, Inc. · NASDAQ:REVBUS$2.39M−US$5.92Mn/an/an/a0.3×n/a0.1×1.66
Mustang Bio, Inc. · NASDAQ:MBIOUS$2.38M−US$11.89Mn/an/an/a0.4×n/a0.0×1.01
Quest PharmaTech Inc. · TSXV:QPTUS$2.36MUS$2.30M0.7×n/an/a0.1×n/a0.0×1.90
HCW Biologics Inc. · NASDAQ:HCWBUS$2.35MUS$8.23Mn/a1.2×n/a0.3×−63.4%1.0×1.19
Ernexa Therapeutics Inc. · NASDAQ:ERNAUS$2.30M−US$2.96Mn/an/an/a0.5×n/a0.1×0.86
Cynata Therapeutics Limited · ASX:CYPUS$2.26MUS$1.66Mn/a1.5×n/an/a−540.4%n/an/a
PharmaCyte Biotech, Inc. · NASDAQ:PMCBUS$2.25M−US$15.59Mn/an/an/a0.1×n/a0.0×1.97
Modus Therapeutics Holding AB · OMXSTO:MODTXUS$2.22MUS$1.00Mn/an/an/a2.2×n/a0.0×n/a
Medicus Pharma Ltd. · NASDAQ:MDCXUS$2.18M−US$2.73Mn/an/an/an/an/an/a2.03
Senti Biosciences Holdings, Inc. · NASDAQ:SNTIUS$2.06M−US$3.49Mn/a−47.2×n/an/an/an/a2.91
Median of the othersUS$2.28M−US$2.85M0.7×1.2×0.3×−301.9%0.0×1.78

Team and board

Officers

OfficerRole
Dan GoodingExecutive Director

Board

DirectorRole
Tim MetcalfeNon-Executive Chairman
Dan GoodingExecutive Director
Maddy KennedyNon-Executive Director

Decks

DeckKindSlidesDate
Investor Presentation (November 2022)Investor deck26 slidesNov 9, 2022
Investor Presentation (April 2021)Investor deck23 slidesApril 2021
Investor Presentation (April 2021)Investor deck23 slidesApril 2021

Open Decks

Financings

RaiseDateIn US dollars
Rights offering of open Offer Shares (ordinary shares)
Announced: about £228,081 · GBX 0.2 a share · CMC Markets UK Plc
Dealers: CMC Markets UK Plc
Use of proceeds: Assess NXP002's inhaled therapeutic window, support partnering and out-licensing talks, maintain key IP, and working capital
Oct 28, 2025US$302,850
Private placement of new ordinary shares
Update: £210,000 · GBX 0.07 a share · CMC Markets UK Plc
Dealers: CMC Markets UK Plc
May 23, 2025US$283,766
Warrant exercise of new ordinary shares
Announced: £13,200 · GBX 0.05 a share
Apr 14, 2025US$17,392
Private placement of new ordinary shares
Announced: £168,750 · GBX 0.0675 a share · CMC Markets UK Plc, trading as CMC CapX
Dealers: CMC Markets UK Plc, trading as CMC CapX (lead)
Use of proceeds: Progress partnering discussions for NXP002 inhaled IPF/PPF programme and general corporate purposes
Jan 30, 2025US$210,182

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in GBP

Income statement

LineFY2025FY2024FY2023FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue00050.0K195.6K535.0K610.0K15.0K0
Cost of revenue28.6K29.2K36.7K038.7K108.8K333.6K537.5K203.9K86.2K
Gross profit-28.6K-29.2K-36.7K011.3K86.7K201.4K72.5K-188.9K-86.2K
Research and development95.3K70.9K163.4K572.9K362.9K525.0K1.45M876.6K472.0K
Selling, general and administrative660.6K506.4K618.6K761.3K1.32K1.51K1.12K911.7K729.0K685.1K
Operating income-660.6K-3.65M-618.6K-761.3K-1.27M-1.37M-918.2K-1.81M-1.96M-685.1K
Depreciation and amortization28.6K29.2K36.7K36.9K37.0K93.1K81.7K52.8K47.4K35.0K
EBITDA-631.9K-3.62M-581.9K-724.4K-1.23M-1.28M-836.5K-1.76M-1.91M-650.0K
Interest expense003.05K15.3K28.4K11.1K1.76K
Income before tax-660.6K-3.65M-618.6K-761.3K-1.27M-1.38M-929.9K-1.84M-1.97M-685.1K
Income tax-7.98K-5.57K-45.7K-1.16K-161.3K-122.2K-173.5K-181.5K-126.8K-68.4K
Net income-652.6K-3.64M-573.0K-760.1K-1.11M-1.25M-756.4K-1.66M-1.84M-685.1K
Earnings per share, basic-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.01

Balance sheet

LineFY2025FY2024FY2023FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents97.5K20.2K202.5K259.3K464.1K1.67M543.8K4.26K338.2K5.89K
Receivables16.1K15.8K116.3K128.5K332.9K138.5K207.2K327.7K350.0K83.2K
Inventory-116.3K-332.9K0-83.2K
Current assets136.1K59.1K336.7K387.8K825.0K1.82M795.7K347.0K713.7K19.6K
Property, plant and equipment43895782.9K27.5K37.5K1.73K
Goodwill882.8K882.8K4.02M4.02M4.02M4.02M4.02M4.02M4.02M
Total assets1.02M970.5K4.42M4.50M4.98M6.01M5.13M4.63M5.03M19.6K
Accounts payable46.3K32.9K69.8K273.6K12.4K99.0K131.0K322.1K89.6K163.4K
Current liabilities263.9K255.0K223.0K273.6K237.9K324.6K346.7K819.5K534.0K199.2K
Total debt75.4K15.1K23.0K187.9K
Total liabilities263.9K255.0K223.0K273.6K237.9K324.6K383.9K819.5K534.0K199.2K
Shareholders' equity754.9K715.6K4.20M4.23M4.74M5.69M4.74M3.82M4.49M-179.6K
Shares outstanding1.66B786.9M719.5M598.4M598.4M580.6M477.1M460.8M373.5M95.8M

Cash flow

LineFY2025FY2024FY2023FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-614.6K-331.9K-546.2K-433.1K-1.35M-848.2K-727.6K-299.3K-1.53M-496.3K
Capital spending00-200-605-43.2K-1.28K-44.1K-93.3K
Free cash flow-614.6K-331.9K-397.5K-433.1K-1.35M-848.8K-770.8K-300.6K-1.58M-589.6K
Cash from investing33.3K43.7K-43.2K-27.3K-100.6K-93.3K
Cash from financing692.0K149.5K189.8K228.3K140.0K1.93M1.31M-7.29K1.97M-19.6K
Change in cash77.3K-182.3K-204.8K-204.8K-1.21M1.13M539.5K-333.9K333.7K-496.3K

Open Financials

Cap table

Built by 6ix from Nuformix PLC’s releases · as of Oct 28, 2025

Common shares
2,609,749,368
Fully diluted
2,609,749,368

Fully diluted

LineShares
Common shares2,609,749,368

Share count over time

CountShares
Nov 22, 20262,609,749,368

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Dan GoodingExecutive Director · Since at least Oct 19, 2026
Maddy KennedyNon-Executive Director · Since at least Nov 5, 2024
Tim MetcalfeNon-Executive Chairman · Since at least Oct 19, 2026

Open People

Log in to ask 6ix AI your own questions about Nuformix PLC.